I read your post and fully agreed to what you said. After...

I read your post and fully agreed to what you said. After reading it I went through the announcement again and I think the way they wrote the statement is not accurate - I don't want to say poorly.

The ELISA reference was in relation to the original study/tests done in 2018 - they don't refer to Luminex platform and the progress done on this BARD1 autoantibody other than - "The Company is exploring several approaches for developing an accurate and reliable blood test for earlier
detection of ovarian cancer utilising its proprietary BARD1 autoantibody (AAb) and SubB2M technologies" - this is to reiterate that is something in the pipeline and is not all about the 2018 Tests - SHOULD HAVE BEEN AT THE END.

My take - "The BARD1 autoantibody approach in the above studies used a research-stage ELISA2 performed on a
research use only MSD3 platform to detect autoantibodies to BARD1 variant proteins. Whilst this has
shown promising data, the Company believes it requires considerable further assay development and
technical validation on a commercial assay platform before advancement towards clinical development of
a potential commercial test." - is only in relation to the 2018 test results



As you can see in the posts people are still not familiar with all the available/future tests and when the announcements are out they get a bit confused.
For those ones that expect clarification/explanation on how the company is progressing and regular updates on ASX - good luck - BD1 is not that kind of company (as yet) - unfortunately - your best chance is to call the company. Sometimes emails work as well.

DYOR and stay safe